Please assess the completion status of the following clinical trial:

Trial Title: Bromfenac Versus Dexamethasone After Cataract Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
INCLUSION CRITERIA~1. Age \> 60 year old.~2. Uneventful cataract surgery. Surgical procedure, as described in the patients chart, should be free of any form of intraoperative complication that may increase postoperative inflammation.~3. Availability of relevant ocular history, including: Best Corrected Visual Acuity testing, Laser Flare Photometry, Optical Coherence Tomography, slit lamp biomicroscopy, intraocular pressure (with pneumotonometer), dilated fundus ophthalmoscopy.~4. Ability and willing to follow all instructions and attend all study visits~5. Ability to self-administer study drug (or have a caregiver available to instill all doses of study drug)~6. Ability and willing to provide informed consent for this study protocol.~7. No ocular, topical, systemic, or inhaled NSAIDs or ocular, topical, or systemic gentamicin, or cyclosporine ophthalmic emulsion within 1 week of investigational product initiation or throughout the duration of the study;~8. No topical, inhaled, or systemic corticosteroids within 15 days or depot corticosteroids within 45 days of the investigational product initiation or or throughout the duration of the study;~9. No oral tamsulosin at any time during the clinical trial;~10. Any ocular, topical, or systemic medication that could interfere with normal lacrimation, wound healing, the investigational product, or the interpretation of clinical trial results.~11. For women, the menopausal state is assumed.~EXCLUSION CRITERIA~1. Ocular exclusion criteria:~   1. history of ocular inflammation or trauma;~  2. history of previous intraocular surgery;~  3. corneal haze, edema or any condition that can interfere with LFP measurement by means of reduced transparency of the cornea;~  4. preoperative LFP value \> 12 ph/ms (as per patient' chart)~  5. pseudoexfoliation lentis;~  6. retinal vascular diseases;~  7. diabetic retinopathy;~  8. any variation of the foveal profile at OCT (including macular edema and epiretinal membranes)~  9. moderate to severe forms of age related macular degeneration~  10. presence of any sign of intraocular inflammation (including cells or flare in the anterior chamber) in either eye (including uveitis);~  11. intraoperative complications during the surgical procedure that may increase postoperative inflammation; this includes, in particular, patients with posterior capsule rupture;~  12. marked intraocular inflammation at postoperative day 1, including keratic precipitates or any form of uveitis;~  13. BCVA ≤ 1/10 in the non study eye~2. Systemic exclusion criteria:~   1. inflammatory diseases;~  2. any active or chronic/recurrent disease that was uncontrolled and was likely to affect wound healing;~  3. severe blood dyscrasia or bone marrow suppression;~  4. uncontrolled/unstable peptic ulcer disease~  5. any uncontrolled/unstable pulmonary, cardiac, vascular, autoimmune, hepatic, renal, or central nervous system disease;~3. Known hypersensitivity to bromfenac or to any component of the investigational products, procedural medications, salicylates, or other NSAIDs.~4. Patients cannot be enrolled in another clinical study concurrently

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Bromfenac (Type: EXPERIMENTAL): Patients randomized to this arm will receive Bromfenac 0.09 % Ophthalmic Solution BID for 2 weeks
- Dexamethasone (Type: ACTIVE_COMPARATOR): Patients randomized to this arm will receive Dexamethasone 0.1 % Ophthalmic Suspension QID for one week and BID for the following week

Based on this trial design, predict the completion outcome and termination type (if applicable).